Search

Your search keyword '"Basta G"' showing total 535 results
Start Over Author "Basta G"
535 results on '"Basta G"'

29. Microencapsulated Umbilical Cord Wharton Jelly-Derived Human Mesenchymal Stem Cells for the Cell Therapy of Type 1 Diabetes Mellitus (T1d): Applications and Limits

Author

Montanucci, P., Pescara, T., Basta, G., and Calafiore, R.

Subjects
Endotoxin-free sodium alginate, Umbilical cord, Wharton jelly-derived human adult mesenchymal stem cells, Endotoxin-free sodium alginate, Microencapsulation, T1D, T1D, Umbilical cord, Microencapsulation, Wharton jelly-derived human adult mesenchymal stem cells
Published
2017

30. Reversal of Hyperglycemia by Microencapsulated Human Umbilical Cord Wharton Jelly-Derived Adult Mesenchymal Stem Cells (hUCMS) Graft (TX) in Spontaneously Nonobese Diabetic (NOD) Mice

Author

Montanucci, P, Pescara, T, Cavallo, M, Parrettini, S, Basta, G, and Calafiore, R.

Subjects
2017 Sponsor(s):Amer Diabet Assoc, Conference: 77th Scientific Sessions of the American-Diabetes-Association Location: San Diego, CA Date: JUN 09-13, Conference: 77th Scientific Sessions of the American-Diabetes-Association Location: San Diego, CA Date: JUN 09-13, 2017 Sponsor(s):Amer Diabet Assoc
Published
2017

36. How to predict new-onset atrial fibrillation in STEMI patients treated by primary percutaneous coronary intervention: The ALBO score

Author

Mazzone, A., primary, Scalese, M., additional, Paradossi, U., additional, Del Turco, S., additional, Botto, N., additional, De Caterina, A., additional, Trianni, G., additional, Ravani, M., additional, Rizza, A., additional, Molinaro, S., additional, Palmieri, C., additional, Berti, S., additional, and Basta, G., additional

Published
2018
Full Text
View/download PDF

41. Islet transplantation versus stem cells for the cell therapy of type 1 diabetes mellitus

Author

Basta, G, Montanucci, Pia, and Calafiore, Riccardo

Subjects
Diabetes Mellitus, Type 1, Diabetes mellitus - Islets of Langerhans transplantation - Stem cells - Insulin - Cell differentiation, Islets of Langerhans Transplantation, Humans, Stem Cell Transplantation
Abstract

Pancreatic islet cell transplantation has represented the mainstay of cell therapy for the potential, final cure of type 1 diabetes mellitus (T1D), along the past two decades. Unfortunately, the restricted availability of cadaveric human donor pancreases coupled with heavy side effects of the recipient's general immunosuppression, have severely crippled progress of this approach into clinical trials. Only a few excellence centers, worldwide, have thus far accrued still quite marginal clinical success. In an attempt to overcome the limits of islet transplantation new technologies for use of several stem cell lineages are being under investigation, with initial experimental evidence of success. Essentially, the actual lines of research involve attempts to either activate native endogenous stem cells that replace diseased/dead cells, by a cell regeneration process, or condition other stem cells to acquire the functional properties of the targeted cells to be substituted (i.e., beta-cell-like elements associated with insulin secretory competence). A wide array of stem cells may fulfill this task, from embryonic (whose use still faces strong ethical barriers), to adult, to induced pluripotent stem cells. Mesenchymal adult stem cells, retrievable from many different sites, including adipose tissue, bone marrow and post-partum umbilical cord Wharton Jelly, seem to couple plastic to immunoregulatory properties that might greatly help progress for the disease cure.

Published
2015

43. Stem cells for the cell and molecular therapy of type 1 diabetes mellitus (T1D): the gap between dream and reality

Author

Calafiore, Riccardo and Basta, G.

Subjects
complications, endocrine system diseases, Insulin, blood glucose, nutritional and metabolic diseases, reversal, Review Article
Abstract

In spite of intense research, over the past 2-3 decades, targeted to validating methods for the cure of T1D, based on cell substitution therapy in the place of exogenously administered insulin injections, achievement of the final goal continues to remain out of reach. In fact, aside of very limited clinical success of the few clinical trials of pancreatic islet cell transplantation in totally immunosuppressed patients with T1D, the vast majority of these diabetic patients invariably is insulin-dependent. New advances for cell and molecular therapy for T1D, including use of stem cells, are reviewed and discussed in an attempt to clearly establish where we are and where are we may go for the final cure for T1DM.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results